|
|
| Line 1: |
Line 1: |
| __NOTOC__
| |
| {{CMG}}
| |
|
| |
|
| ===''[[Spironolactone|Spironolactone]]''===
| |
|
| |
| * [[Aldactone]]
| |
|
| |
| ===''[[Spironolactone/Hydrochlorothiazide|Spironolactone/Hydrochlorothiazide]]''===
| |
|
| |
| * [[Aldactazide]]
| |
|
| |
| ==Overview==
| |
|
| |
| Spironolactone is a competitive, [[Beta-1 adrenergic receptor|β<sub>1</sub>]]-selective (cardioselective) [[beta blocker|blocker]] used in treatment of [[angina pectoris]], [[hypertension]], [[arrhythmia]], and [[migraine]]. Common adverse reactions include [[bradyarrhythmia]], [[heart block]], [[heart failure]], [[hypotension]], [[pruritus]], [[rash]], [[constipation]], [[diarrhea]], [[indigestion]], [[nausea]], [[dizziness]], [[fatigue]], [[headache]], [[depression]], [[dyspnea]], and [[wheezing]].
| |
|
| |
| The active substance metoprolol is employed either as ''metoprolol [[succinic acid|succinate]]'' or as ''metoprolol [[tartrate]]''. The [[tartrate]] is an immediate-release and the [[succinic acid|succinate]] is an extended-release [[Pharmaceutical formulation|formulation]].
| |
|
| |
| ==Category==
| |
|
| |
| Aldosterone Antagonist
| |